Half-year report · HY
4361.TEDINET S100YP26
Period2025-12-01 → 2026-05-31
Filed2026-07-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.3bn | 2025-12-01 → 2026-05-31 | Cons. | Net sales |
| Revenue | ¥8.8bn | 2024-12-01 → 2025-11-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.3bn | 2024-12-01 → 2025-05-31 | Cons. | Net sales |
| Operating income | ¥304m | 2025-12-01 → 2026-05-31 | Cons. | Operating income |
| Operating income | ¥199m | 2024-12-01 → 2025-05-31 | Cons. | Operating income |
| Ordinary income | ¥285m | 2025-12-01 → 2026-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥405m | 2024-12-01 → 2025-11-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥183m | 2024-12-01 → 2025-05-31 | Cons. | Ordinary income |
| Profit before tax | ¥288m | 2025-12-01 → 2026-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥183m | 2024-12-01 → 2025-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥209m | 2025-12-01 → 2026-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥298m | 2024-12-01 → 2025-11-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥135m | 2024-12-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥209m | 2025-12-01 → 2026-05-31 | Cons. | Profit loss |
| Net income | ¥135m | 2024-12-01 → 2025-05-31 | Cons. | Profit loss |
| Total assets | ¥9.0bn | at 2026-05-31 | Cons. | Assets |
| Total assets | ¥8.9bn | at 2025-11-30 | Cons. | Assets |
| Total assets | ¥8.8bn | at 2025-05-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.7bn | at 2026-05-31 | Cons. | Liabilities |
| Total liabilities | ¥5.7bn | at 2025-11-30 | Cons. | Liabilities |
| Net assets / equity | ¥3.3bn | at 2026-05-31 | Cons. | Net assets |
| Net assets / equity | ¥3.1bn | at 2025-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.9bn | at 2025-05-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.0bn | at 2026-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.2bn | at 2025-11-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.0bn | at 2026-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.2bn | at 2025-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥745m | at 2024-11-30v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.1bn | 2025-12-01 → 2026-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥830m | 2024-12-01 → 2025-11-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥566m | 2024-12-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥138m | 2025-12-01 → 2026-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥739m | 2024-12-01 → 2025-11-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥216m | 2024-12-01 → 2025-05-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥228m | 2025-12-01 → 2026-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥360m | 2024-12-01 → 2025-11-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥187m | 2024-12-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥171.92 | 2025-12-01 → 2026-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥245.11 | 2024-12-01 → 2025-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥110.52 | 2024-12-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 36.6% | at 2026-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.3% | at 2025-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.5% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceutical Productsreportable segment | revenue | 2025-12-01 → 2026-05-31 | ¥4.3bn |
| Pharmaceutical Productsreportable segment | revenue external | 2025-12-01 → 2026-05-31 | ¥4.3bn |
| Pharmaceutical Productsreportable segment | segment profit | 2025-12-01 → 2026-05-31 | ¥288m |
| Real Estate Leasingreportable segment | revenue | 2025-12-01 → 2026-05-31 | ¥19m |
| Real Estate Leasingreportable segment | revenue external | 2025-12-01 → 2026-05-31 | ¥19m |
| Real Estate Leasingreportable segment | segment profit | 2025-12-01 → 2026-05-31 | ¥15m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-12-01 → 2026-05-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-12-01 → 2026-05-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-12-01 → 2026-05-31 | ¥304m |
| Pharmaceutical Productsreportable segment | revenue | 2024-12-01 → 2025-05-31 | ¥4.3bn |
| Pharmaceutical Productsreportable segment | revenue external | 2024-12-01 → 2025-05-31 | ¥4.3bn |
| Pharmaceutical Productsreportable segment | segment profit | 2024-12-01 → 2025-05-31 | ¥184m |
| Real Estate Leasingreportable segment | revenue | 2024-12-01 → 2025-05-31 | ¥19m |
| Real Estate Leasingreportable segment | revenue external | 2024-12-01 → 2025-05-31 | ¥19m |
| Real Estate Leasingreportable segment | segment profit | 2024-12-01 → 2025-05-31 | ¥15m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-12-01 → 2025-05-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-12-01 → 2025-05-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-12-01 → 2025-05-31 | ¥199m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 480
| Item | Context | Value | Unit |
|---|---|---|---|
| Name of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)川口化学工業株式会社 | |
| Address of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)東京都千代田区内神田２丁目８番４号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | InterimDuration | Text · Plus | |
| Note on independent audit financial information | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated balance sheet (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of comprehensive income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of cash flows (text) | InterimDuration | Text · Plus | |
| Notes uncertainties of entitys ability to continue as going concern semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes changes in scope of consolidation or equity method (text) | InterimDuration | Text · Plus | |
| Notes accounting treatments specific to semi annual financial statements type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes regarding promissory notes due on balance sheet date (text) | InterimInstant | Text · Plus | |
| Major components of selling general and administrative expenses (text) | InterimDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1InterimDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | InterimDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | InterimDuration | Text · Plus | |
| Notes segment information etc type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1InterimDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | InterimDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | InterimDuration | Text · Plus | |
| Notes revenue recognition semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes per share information semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes significant events after reporting period semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | InterimDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |